Payment overview · 2025
General Payments
$406.28
22 reported records · 12 companies
Healthcare provider profile · identity verified
Grant E Hawkins, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SANDY, UT · NPI 1255341806
Verified facts
What the public records show
CMS Open Payments records show Grant E Hawkins, MD received $406.28 in general payments during 2025 across 22 reported records.
Amgen Inc. accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.46 | 19.3% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $64.54 | 15.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.84 | 11.8% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.90 | 9.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.96 | 8.6% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $31.54 | 7.8% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $28.07 | 6.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.86 | 5.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.62 | 4.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.87 | 3.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.20 | 3.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.42 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $406.28 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $64.54 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $47.28 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $31.54 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.84 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $28.44 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $28.07 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
148 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 776 | 210 |
| Atorvastatin Calcium | Atorvastatin Calcium | 747 | 224 |
| Losartan Potassium | Losartan Potassium | 675 | 196 |
| Omeprazole | Omeprazole | 549 | 164 |
| Tamsulosin Hcl | Tamsulosin Hcl | 419 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 130 |
| Trazodone Hcl | Trazodone Hcl | 413 | 116 |
| Simvastatin | Simvastatin | 390 | 107 |
| Lisinopril | Lisinopril | 384 | 115 |
| Meloxicam | Meloxicam | 375 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 341 | 106 |
| Gabapentin | Gabapentin | 307 | 90 |
| Zolpidem Tartrate | Zolpidem Tartrate | 291 | 62 |
| Eliquis | Apixaban | 277 | 66 |
| Potassium Chloride | Potassium Chloride | 274 | 99 |
| Metformin Hcl | Metformin Hcl | 269 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 73 |
| Alprazolam | Alprazolam | 229 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 212 | 42 |
| Celecoxib | Celecoxib | 201 | 73 |
| Furosemide | Furosemide | 192 | 69 |
| Montelukast Sodium | Montelukast Sodium | 187 | 62 |
| Glimepiride | Glimepiride | 186 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 67 |
| Fluoxetine Hcl | Fluoxetine Hcl | 177 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 49 |
| Estradiol | Estradiol | 168 | 54 |
| Tramadol Hcl | Tramadol Hcl | 161 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 41 |
| Ozempic | Semaglutide | 148 | 23 |
| Donepezil Hcl | Donepezil Hcl | 145 | 46 |
| Finasteride | Finasteride | 134 | 34 |
| Sertraline Hcl | Sertraline Hcl | 133 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 41 |
| Metformin Hcl Er | Metformin Hcl | 120 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 36 |
| Clonazepam | Clonazepam | 117 | 21 |
| Carvedilol | Carvedilol | 107 | 36 |
| Bupropion Hcl Sr | Bupropion Hcl | 98 | 32 |
| Allopurinol | Allopurinol | 97 | 30 |
| Spironolactone | Spironolactone | 97 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 94 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 28 |
| Lorazepam | Lorazepam | 89 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 25 |
| Ibuprofen | Ibuprofen | 75 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 36 |
| Memantine Hcl | Memantine Hcl | 68 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 67 | 28 |
| Xarelto | Rivaroxaban | 67 | 11 |
| Bupropion Xl | Bupropion Hcl | 65 | 20 |
| Warfarin Sodium | Warfarin Sodium | 65 | 20 |
| Methylprednisolone | Methylprednisolone | 63 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 24 |
| Diazepam | Diazepam | 58 | 12 |
| Prednisone | Prednisone | 58 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 56 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 56 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 16 |
| Azithromycin | Azithromycin | 50 | 34 |
| Amoxicillin | Amoxicillin | 46 | 37 |
| Clonidine Hcl | Clonidine Hcl | 46 | 12 |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Topiramate | Topiramate | 43 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 13 |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 38 | 13 |
| Valacyclovir | Valacyclovir Hcl | 38 | 25 |
| Temazepam | Temazepam | 37 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Atenolol | Atenolol | 34 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 31 | suppressed |
| Cefdinir | Cefdinir | 31 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 20 |
| Meclizine Hcl | Meclizine Hcl | 28 | 17 |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 13 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Pregabalin | Pregabalin | 24 | 12 |
| Fluconazole | Fluconazole | 23 | 20 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | 11 |
| Torsemide | Torsemide | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Progesterone | Progesterone, Micronized | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $406.28 · 22 records | Amgen Inc. | AIRSUPRA, DALVANCE, DOVATO, Dexcom G6 Transmitter, EVENITY, INSPIRE, JARDIANCE, MINIMED 780G, MOUNJARO, NUZYRA, OPSUMIT, OTEZLA, PROLIA, REPATHA, Wegovy, XHANCE, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error